Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: Once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2297-2302

  Fukushima, Toshihiro ^a   Nakamura, Takuji ^a   Iwao, Haruka ^a   Nakajima, Akio ^a   Miki, Miyuki ^a   Sato, Tomomi ^a   Sakai, Tomoyuki ^a   Sawaki, Toshioki ^a   Fujita, Yoshimasa ^a   Tanaka, Masao ^a   Masaki, Yasufumi ^a   Nakajima, Hideo ^a   Motoo, Yoshiharu ^a   Umehara, Hisanori ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bortezomib; Dexamethasone; Gastrointestinal adverse events; Multiple myeloma; Once weekly administration

Indexed keywords

ALANINE AMINOTRANSFERASE; BORTEZOMIB; C REACTIVE PROTEIN; CREATININE; DEXAMETHASONE; HEMOGLOBIN; VALACICLOVIR;

ADULT; AGE; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENDER; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; LEUKOPENIA; LUNG DISEASE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 79960440595     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. The International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003.
2. Kyle RA and Rajkumar SV: Multiple myeloma. Blood 111: 2962-2972, 2008.
3. Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B and Vanderkerken K: Multiple myeloma□an update on diagnosis and treatment. Eur J Haematol 81: 329-343, 2008.
4. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534, 2003. (Pubitemid 36182530)
5. Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598, 2007. (Pubitemid 47106630)
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003. (Pubitemid 36741588)
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D and Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
8. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H and Richardson PG; VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
9. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I and Westin J: International Staging System for multiple myeloma. J Clin Oncol 23: 3412-3420, 2005.
10. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G and Rajkumar SV: International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006. (Pubitemid 44264086)
11. National Cancer Institute: National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0. 9 August 2006. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-30.
12. Fukushima T, Nakamura T, Miki M, Sakai T, Iwao H, Nakajima A, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Hirose Y and Umehara H: Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas. Anticancer Res 30: 3791-3794, 2010.
13. Igarashi N, Chou T, Hirose T, Imai Y and Ishiguro T: Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. Int J Hematol 92: 518-523, 2010.
14. Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, Tanaka T, Kamitsuji Y, Murakami S, Hatsuse M, Okano A, Iwai T, Ueda S, Koshida M, Uchiyama H, Matsumoto Y, Kaneko H, Uoshima N, Ueda Y, Kobayashi Y, Shimazaki C, Horiike S and Taniwaki M: Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol 92: 579-586, 2010.
15. Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosinol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC and Bladé J: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143: 46-53, 2008.
16. Suvannasankha A, Smith GG, Juliar BE and Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 7: 131-134, 2006.
17. Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J and Greco FA: Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 113: 765-771, 2008.
18. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G and Boccadoro M: Bortezomib-melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28: 5101-5109, 2010.
19. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M and Palumbo A: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116: 4745-4753, 2010.
20. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A and Spriggs DR: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8: 2505-2511, 2002. (Pubitemid 34856332)
21. Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, Taji H, Minami H, Itoh K, Nakata M and Hotta T: Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 99: 140-144, 2008. (Pubitemid 350239042)